Primary Sclerosing Cholangitis pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook
2020 Primary Sclerosing Cholangitis PIPELINE HIGHLIGHTS
Primary Sclerosing Cholangitis is one of the widely researched conditions during 2020 with 19 companies actively focusing on realizing pipeline’s potential. Development of Primary Sclerosing Cholangitis medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Primary Sclerosing Cholangitis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Primary Sclerosing Cholangitis.
Good progress is anticipated during 2020 and 2021 with Primary Sclerosing Cholangitis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Primary Sclerosing Cholangitis pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Primary Sclerosing Cholangitis DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Primary Sclerosing Cholangitis pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Primary Sclerosing Cholangitis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
The competitive intelligence report on Primary Sclerosing Cholangitis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Primary Sclerosing Cholangitis pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Primary Sclerosing Cholangitis DRUG PROFILES
Primary Sclerosing Cholangitis development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
Both small size and large size pharmaceutical companies are investing their resources in Primary Sclerosing Cholangitis drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Primary Sclerosing Cholangitis. Partnerships and acquisitions are also increasingly observed in the pipeline.
This research report presents an analysis of 19 Primary Sclerosing Cholangitis companies including company overview, key snapshot, contact information, and their strategies on accelerating Primary Sclerosing Cholangitis pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.
Companies analyzed in the report include- Albireo Pharma Inc, BiomX Inc, ChemomAb Ltd, Dr Falk Pharma GMBH, Engitix Ltd, Gilead Sciences Inc, HighTide Biopharma, Immunic Inc, Intercept Pharmaceuticals Inc , Mirum Pharmaceuticals Inc, Morphic Holding Inc, NGM Biopharmaceuticals Inc, Nyrada Inc, Orbsen Therapeutics Ltd , Pliant Therapeutics Inc, Seres Therapeutics Inc, Sirnaomics Inc, Takeda Pharmaceutical Co Ltd, Tobira Therapeutics Inc
REASONS TO BUY
Primary Sclerosing Cholangitis is one of the widely researched conditions during 2020 with 19 companies actively focusing on realizing pipeline’s potential. Development of Primary Sclerosing Cholangitis medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Primary Sclerosing Cholangitis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Primary Sclerosing Cholangitis.
Good progress is anticipated during 2020 and 2021 with Primary Sclerosing Cholangitis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Primary Sclerosing Cholangitis pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Primary Sclerosing Cholangitis DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Primary Sclerosing Cholangitis pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Primary Sclerosing Cholangitis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
The competitive intelligence report on Primary Sclerosing Cholangitis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Primary Sclerosing Cholangitis pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Primary Sclerosing Cholangitis DRUG PROFILES
Primary Sclerosing Cholangitis development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
- Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
- Phase of development
- Mechanism of Action
- Route of Administration
- Companies involved including originator, licensing companies, developer, investors, and others
- New molecular entity details
- Orphan drug designation and other special status provided by regulators
Both small size and large size pharmaceutical companies are investing their resources in Primary Sclerosing Cholangitis drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Primary Sclerosing Cholangitis. Partnerships and acquisitions are also increasingly observed in the pipeline.
This research report presents an analysis of 19 Primary Sclerosing Cholangitis companies including company overview, key snapshot, contact information, and their strategies on accelerating Primary Sclerosing Cholangitis pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.
Companies analyzed in the report include- Albireo Pharma Inc, BiomX Inc, ChemomAb Ltd, Dr Falk Pharma GMBH, Engitix Ltd, Gilead Sciences Inc, HighTide Biopharma, Immunic Inc, Intercept Pharmaceuticals Inc , Mirum Pharmaceuticals Inc, Morphic Holding Inc, NGM Biopharmaceuticals Inc, Nyrada Inc, Orbsen Therapeutics Ltd , Pliant Therapeutics Inc, Seres Therapeutics Inc, Sirnaomics Inc, Takeda Pharmaceutical Co Ltd, Tobira Therapeutics Inc
REASONS TO BUY
- The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
- This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
- Buyers can identify most promising drug candidates for treatment of Primary Sclerosing Cholangitis
- It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
- Users can estimate possible delays in the delivery of pipeline or launch of new products
- Stay ahead of competition through understanding their pipeline progression, strategies and outlook
- The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
- Optimize your licensing and technology transfer strategies through identification of prospect partners
1. INTRODUCTION TO PRIMARY SCLEROSING CHOLANGITIS
1.1 Primary Sclerosing Cholangitis- Disease overview
1.2 Primary Sclerosing Cholangitis- Market Size
1.3 Primary Sclerosing Cholangitis- Companies Involved
2. PRIMARY SCLEROSING CHOLANGITIS PIPELINE SNAPSHOT- 2020
2.1 Primary Sclerosing Cholangitis Pipeline by Phase
2.2 Primary Sclerosing Cholangitis Pipeline by Mechanism of Action
2.3 Primary Sclerosing Cholangitis Pipeline by Route of Administration
2.4 Primary Sclerosing Cholangitis Pipeline- New Molecular Entities
2.5 Primary Sclerosing Cholangitis Pipeline- Orphan Drug Designation/ Special Designation
3. PRIMARY SCLEROSING CHOLANGITIS DRUG PROFILES
3.1 Current Status
3.2 Primary Sclerosing Cholangitis Drug Snapshot
3.3 Primary Sclerosing Cholangitis Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Albireo Pharma Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.2 BiomX Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.3 ChemomAb Ltd Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.4 Dr Falk Pharma GMBH Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.5 Engitix Ltd Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.6 Gilead Sciences Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.7 HighTide Biopharma Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.8 Immunic Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.9 Intercept Pharmaceuticals Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.10 Mirum Pharmaceuticals Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.11 Morphic Holding Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.12 NGM Biopharmaceuticals Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.13 Nyrada Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.14 Orbsen Therapeutics Ltd Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.15 Pliant Therapeutics Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.16 Seres Therapeutics Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.17 Sirnaomics Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.18 Takeda Pharmaceutical Co Ltd Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.19 Tobira Therapeutics Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
5. PRIMARY SCLEROSING CHOLANGITIS MARKET NEWS AND UPDATES
6. APPENDIX
6.1 Sources and Methodology
6.2 Contact Information
1.1 Primary Sclerosing Cholangitis- Disease overview
1.2 Primary Sclerosing Cholangitis- Market Size
1.3 Primary Sclerosing Cholangitis- Companies Involved
2. PRIMARY SCLEROSING CHOLANGITIS PIPELINE SNAPSHOT- 2020
2.1 Primary Sclerosing Cholangitis Pipeline by Phase
2.2 Primary Sclerosing Cholangitis Pipeline by Mechanism of Action
2.3 Primary Sclerosing Cholangitis Pipeline by Route of Administration
2.4 Primary Sclerosing Cholangitis Pipeline- New Molecular Entities
2.5 Primary Sclerosing Cholangitis Pipeline- Orphan Drug Designation/ Special Designation
3. PRIMARY SCLEROSING CHOLANGITIS DRUG PROFILES
3.1 Current Status
3.2 Primary Sclerosing Cholangitis Drug Snapshot
3.3 Primary Sclerosing Cholangitis Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Albireo Pharma Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.2 BiomX Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.3 ChemomAb Ltd Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.4 Dr Falk Pharma GMBH Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.5 Engitix Ltd Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.6 Gilead Sciences Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.7 HighTide Biopharma Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.8 Immunic Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.9 Intercept Pharmaceuticals Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.10 Mirum Pharmaceuticals Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.11 Morphic Holding Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.12 NGM Biopharmaceuticals Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.13 Nyrada Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.14 Orbsen Therapeutics Ltd Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.15 Pliant Therapeutics Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.16 Seres Therapeutics Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.17 Sirnaomics Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.18 Takeda Pharmaceutical Co Ltd Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
4.19 Tobira Therapeutics Inc Primary Sclerosing Cholangitis Pipeline Insights and Clinical Trials
5. PRIMARY SCLEROSING CHOLANGITIS MARKET NEWS AND UPDATES
6. APPENDIX
6.1 Sources and Methodology
6.2 Contact Information
